

# Chim C Lang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4564467/publications.pdf>

Version: 2024-02-01

235  
papers

15,074  
citations

18465

62  
h-index

20943

115  
g-index

238  
all docs

238  
docs citations

238  
times ranked

18475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and the risk of myocardial infarction in 27â€™000 participants from 52 countries: a case-control study. <i>Lancet, The</i> , 2005, 366, 1640-1649.	6.3	2,414
2	Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. <i>Circulation Research</i> , 2016, 119, 652-665.	2.0	498
3	Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 294-299.	1.6	491
4	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.	5.8	466
5	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of reninâ€™angiotensinâ€™aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
6	Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. <i>Lancet, The</i> , 2010, 375, 2161-2167.	6.3	301
7	Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 76, 1259-1265.	0.7	296
8	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet, The</i> , 2011, 378, 676-683.	6.3	295
9	Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. <i>Journal of the American College of Cardiology</i> , 2007, 49, 687-694.	1.2	268
10	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.	1.6	229
11	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
12	High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. <i>European Heart Journal</i> , 2014, 35, 2312-2321.	1.0	193
13	Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1382-1389.	3.0	191
14	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
15	The clinical significance of interleukinâ€™6 in heart failure: results from the BIOSTATâ€™CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	2.9	172
16	Normalization of Acquired QT Prolongation in Humans by Intravenous Potassium. <i>Circulation</i> , 1997, 96, 2149-2154.	1.6	163
17	Attenuation of Isoproterenol-Mediated Vasodilatation in Blacks. <i>New England Journal of Medicine</i> , 1995, 333, 155-160.	13.9	160
18	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	6.3	159

#	ARTICLE	IF	CITATIONS
19	A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSSTAT&#x2013;CHF</scp>. European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149
20	Hemodynamic Exercise Testing. Circulation, 1996, 94, 3176-3183.	1.6	149
21	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. Circulation, 2020, 142, 1713-1724.	1.6	144
22	Cardiovascular Effects of Switching From&#x2013;Tobacco Cigarettes to Electronic&#x2013;Cigarettes. Journal of the American College of Cardiology, 2019, 74, 3112-3120.	1.2	143
23	Vasodilation in black Americans: Attenuated nitric oxide-mediated responses*. Clinical Pharmacology and Therapeutics, 1997, 62, 436-443.	2.3	142
24	Impact of Renin-Angiotensin System Blockade Therapy on Outcome in Aortic Stenosis. Journal of the American College of Cardiology, 2011, 58, 570-576.	1.2	142
25	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
26	AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clinical Science, 2009, 116, 607-620.	1.8	139
27	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal, 2020, 41, 3421-3432.	1.0	138
28	High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease. Journal of the American College of Cardiology, 2013, 61, 926-932.	1.2	132
29	Increased Vascular Adrenergic Vasoconstriction and Decreased Vasodilation in Blacks. Hypertension, 2000, 36, 945-951.	1.3	127
30	Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 1996, 78, 284-287.	0.7	123
31	Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). European Heart Journal, 2014, 35, 1255-1262.	1.0	121
32	Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clinical Science, 2008, 115, 295-300.	1.8	120
33	Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. American Heart Journal, 1994, 127, 1635-1636.	1.2	112
34	Mechanistic Insights Into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris. Journal of the American College of Cardiology, 2011, 58, 820-828.	1.2	110
35	Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clinical Science, 1992, 83, 519-527.	1.8	107
36	Peak Cardiac Power Output, Measured Noninvasively, Is a Powerful Predictor of Outcome in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 33-38.	1.6	106

#	ARTICLE	IF	CITATIONS
37	Non-cardiac comorbidities in chronic heart failure. <i>Heart</i> , 2007, 93, 665-671.	1.2	102
38	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <i>Diabetes Care</i> , 2020, 43, 1356-1359.	4.3	102
39	Repurposing Metformin for Cardiovascular Disease. <i>Circulation</i> , 2018, 137, 422-424.	1.6	100
40	A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. <i>European Heart Journal</i> , 2019, 40, 3409-3417.	1.0	100
41	Allopurinol Reduces Left Ventricular Mass in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2284-2293.	1.2	97
42	The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 262-272.	0.8	96
43	Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2010, 106, 1006-1010.	0.7	89
44	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 38.	1.0	89
45	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
46	Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 747-753.	1.2	84
47	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1415-1423.	2.9	84
48	Ease of Noninvasive Measurement of Cardiac Output Coupled With Peak VO <sub>2</sub> Determination at Rest and During Exercise in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2007, 99, 404-405.	0.7	82
49	The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 1303-1310.	2.9	79
50	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <sc>BIOSTATâ€œCHF</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
51	Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. <i>Journal of the American College of Cardiology</i> , 1998, 32, 117-122.	1.2	78
52	Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 125-134.	6.1	78
53	Mean <sc>HbA<sub>1c</sub></sc> and mortality in diabetic individuals with heart failure: a population cohort study. <i>European Journal of Heart Failure</i> , 2016, 18, 94-102.	2.9	76
54	Improving the Primary Prevention of Cardiovascular Events by Using Biomarkers to Identify Individuals With Silent Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 960-968.	1.2	75

#	ARTICLE	IF	CITATIONS
55	A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 1021-1026.	0.7	73
56	Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Mlcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. <i>European Heart Journal</i> , 2017, 38, 1222-1229.	1.0	72
57	Sacubitril/valsartan: beyond natriuretic peptides. <i>Heart</i> , 2017, 103, 1569-1577.	1.2	72
58	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	2.9	70
59	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019, 40, 3616-3625.	1.0	69
60	The Impact of Renin-Angiotensin-Aldosterone System Blockade on Heart Failure Outcomes and Mortality in Patients Identified to Have Aortic Regurgitation. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2084-2091.	1.2	68
61	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	2.9	68
62	Effect of Sympathoinhibition on Exercise Performance in Patients With Heart Failure. <i>Circulation</i> , 1997, 96, 238-245.	1.6	67
63	Dietary sodium loading increases plasma brain natriuretic peptide levels in man. <i>Journal of Hypertension</i> , 1991, 9, 779-782.	0.3	66
64	A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study. <i>BMJ Open</i> , 2018, 8, e019649.	0.8	66
65	Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1602-1608.	1.2	64
66	Prognostic Significance and Measurement of Exercise-Derived Hemodynamic Variables in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 672-679.	0.7	64
67	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 732-743.	2.9	64
68	Symptom Onset in Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 96-105.	2.3	62
69	The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. <i>European Heart Journal</i> , 2007, 28, 1678-1682.	1.0	61
70	Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction: A randomised controlled trial. <i>International Journal of Cardiology</i> , 2013, 167, 745-749.	0.8	60
71	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). <i>International Journal of Epidemiology</i> , 2018, 47, 380-381j.	0.9	59
72	Efficacy and Cost of an Exercise Program for Functionally Impaired Older Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 209-216.	1.6	57

#	ARTICLE	IF	CITATIONS
73	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57
74	Clinical Role of CA125 in Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 386-397.	1.9	57
75	Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 41-46.	2.3	55
76	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
77	Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: Clinical evidence and pathophysiological mechanisms. <i>Atherosclerosis</i> , 2010, 212, 1-8.	0.4	53
78	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
79	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. <i>Cardiovascular Diabetology</i> , 2016, 15, 97.	2.7	49
80	Skeletal muscle mass and exercise performance in stable ambulatory patients with heart failure. <i>Journal of Applied Physiology</i> , 1997, 82, 257-261.	1.2	48
81	Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. <i>European Journal of Heart Failure</i> , 2012, 14, 162-167.	2.9	48
82	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
83	Altered coronary vasomotor function in young patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1904-1909.	6.7	46
84	COVID-19-Associated Cardiovascular Complications. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 47.	1.0	45
85	Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 332-335.	1.1	44
86	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	2.9	44
87	Morbidity and mortality in diabetic patients following cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 244-249.	0.3	43
88	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
89	Abnormalities of the QT interval in primary disorders of autonomic failure. <i>American Heart Journal</i> , 1998, 136, 664-671.	1.2	42
90	The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 280-288.	4.4	42

#	ARTICLE	IF	CITATIONS
91	Cardiopulmonary Exercise Variables in Diastolic Versus Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 203-206.	0.7	42
92	Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 69-72.	1.1	41
93	Insulin Resistance: A Potential New Target for Therapy in Patients with Heart Failure. <i>Cardiovascular Therapeutics</i> , 2008, 26, 203-213.	1.1	41
94	Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2015, 8, 236-242.	1.6	41
95	Measurement of coronary vasomotor function: getting to the heart of the matter in cardiovascular research. <i>Clinical Science</i> , 2004, 107, 449-460.	1.8	40
96	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. <i>BMJ Open</i> , 2017, 7, e018097.	0.8	38
97	Resting Heart Rate and Outcomes in Patients with Cardiovascular Disease: Where Do We Currently Stand?. <i>Cardiovascular Therapeutics</i> , 2013, 31, 215-223.	1.1	37
98	Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 31.	0.7	36
99	The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1252-1261.	0.8	36
100	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
101	Efficacy of noninvasive cardiac imaging tests in diagnosis and management of stable coronary artery disease. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 427-437.	1.0	34
102	Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. <i>Diseases (Basel, Switzerland)</i> , 2017, 5, 14.	1.0	34
103	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
104	Usefulness of Non-Invasive Measurement of Cardiac Output During Sub-Maximal Exercise to Predict Outcome in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2009, 104, 1556-1560.	0.7	32
105	Pacing-induced heart disease: understanding the pathophysiology and improving outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 877-886.	0.6	32
106	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
107	Iron Therapy in Heart Failure: Ready for Primetime?. <i>Cardiac Failure Review</i> , 2018, 4, 1.	1.2	31
108	Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 95-110.	5.7	30

#	ARTICLE	IF	CITATIONS
109	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
110	Blunted Blood Pressure Response to Central Sympathoinhibition in Normotensive Blacks. <i>Hypertension</i> , 1997, 30, 157-162.	1.3	29
111	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	1.5	28
112	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
113	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	2.9	28
114	Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. <i>International Journal of Cardiology</i> , 2013, 167, 2695-2699.	0.8	27
115	Coronary Vasomotor Function Is Abnormal in First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 150-153.	4.3	26
116	Therapeutic Development in Cardiac Syndrome X: A Need to Target the Underlying Pathophysiology. <i>Cardiovascular Therapeutics</i> , 2009, 27, 49-58.	1.1	26
117	Management of Noncardiac Comorbidities in Chronic Heart Failure. <i>Cardiovascular Therapeutics</i> , 2015, 33, 300-315.	1.1	26
118	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	2.9	26
119	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 229.	0.7	25
120	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	2.9	25
121	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 218-226.	2.9	25
122	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	1.9	25
123	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	2.9	24
124	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <sc>BIOSTAT-CHF</sc> and <sc>ASIAN-CHF</sc> registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	2.9	24
125	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. <i>Lancet, The</i> , 2015, 385, S26.	6.3	23
126	Adverse prognosis associated with asymmetric myocardial thickening in aortic stenosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 347-356.	0.5	23



#	ARTICLE	IF	CITATIONS
127	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005544.	1.6	23
128	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 746382.	1.1	23
129	Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. <i>Annals of Internal Medicine</i> , 2022, 175, 851-861.	2.0	23
130	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
131	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020, 20, 770-783.	0.9	22
132	Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 419-426.	0.3	21
133	Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, heartjnl-2019-314763.	1.2	20
134	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTATâ€CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 436-444.	2.9	20
135	Higher doses of loop diuretics limit up-titration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20
136	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTATâ€CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	2.9	20
137	Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
138	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020, 41, 1606-1607.	1.0	18
139	Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2021, 44, 1699-1705.	4.3	18
140	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. <i>Vascular Health and Risk Management</i> , 2015, 11, 283.	1.0	17
141	Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts. <i>EBioMedicine</i> , 2017, 18, 171-178.	2.7	17
142	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
143	Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. <i>Journal of Hypertension</i> , 2019, 37, 2481-2489.	0.3	17
144	Metformin and its Effects on Myocardial Dimension and Left ventricular hypertrophy in Normotensive patients with Coronary Heart Disease (The <sc>MET</sc>-<sc>REMODEL</sc> Study): Rationale and Design of the <sc>MET</sc>-<sc>REMODEL</sc> Study. <i>Cardiovascular Therapeutics</i> , 2015, 33, 1-8.	1.1	16

#	ARTICLE	IF	CITATIONS
145	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
146	Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration. <i>Circulation</i> , 2020, 142, 1117-1119.	1.6	16
147	The role of cardiac biochemical markers in aortic stenosis. <i>Biomarkers</i> , 2016, 21, 316-327.	0.9	15
148	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
149	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
150	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>Tj ETQq0 0 0 rgBT /Overlock 10Tf 50 32</i>	1.5	15
151	Insulin Sensitization Therapy and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, 539-550.	1.0	14
152	Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis. <i>Cardiovascular Diabetology</i> , 2013, 12, 109.	2.7	14
153	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 1168-1177.	1.4	14
154	Effect of CYP3A inhibition on vesnarinone metabolism in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 506-511.	2.3	13
155	Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12301.	1.1	12
156	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSAT-CHF. <i>European Journal of Internal Medicine</i> , 2020, 71, 62-69.	1.0	12
157	Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 668-674.	2.3	11
158	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
159	Metformin: still the sweet spot for CV protection in diabetes?. <i>Current Opinion in Pharmacology</i> , 2020, 54, 202-208.	1.7	11
160	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
161	Potential mechanisms for the effects of far-infrared on the cardiovascular system – a review. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 303-312.	0.6	11
162	Prediction of Major Adverse Cardiovascular Events From Retinal, Clinical, and Genomic Data in Individuals With Type 2 Diabetes: A Population Cohort Study. <i>Diabetes Care</i> , 2022, 45, 710-716.	4.3	11

#	ARTICLE	IF	CITATIONS
163	Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study. <i>European Journal of Heart Failure</i> , 2015, 17, 90-97.	2.9	10
164	An Increased B-Type Natriuretic Peptide in the Absence of a Cardiac Abnormality Identifies Those Whose Left Ventricular Mass Will Increase Over Time. <i>JACC: Heart Failure</i> , 2015, 3, 87-93.	1.9	10
165	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
166	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSAT-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
167	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
168	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	2.9	10
169	Right ventricular pacing impairs endothelial function in man. <i>Europace</i> , 2011, 13, 853-858.	0.7	9
170	Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12258.	1.1	9
171	Differential Association of Genetic Risk of Coronary Artery Disease With Development of Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Circulation</i> , 2019, 139, 986-988.	1.6	9
172	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. <i>International Journal of Cardiology</i> , 2019, 276, 212-217.	0.8	9
173	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020, 7, 953-963.	1.4	9
174	Biomarkers of Aortopathy in Marfan Syndrome. <i>Cardiology in Review</i> , 2020, 28, 92-97.	0.6	9
175	Process evaluation of a randomised pilot trial of home-based rehabilitation compared to usual care in patients with heart failure with preserved ejection fraction and their caregivers. <i>Pilot and Feasibility Studies</i> , 2021, 7, 11.	0.5	9
176	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	2.9	9
177	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e019123.	1.6	9
178	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	2.9	9
179	Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors?. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 107-114.	0.6	8
180	Characterizing Patients with Chronic Heart Failure in Community Care After Hospitalization: A Potential Role for Ivabradine. <i>Cardiovascular Therapeutics</i> , 2015, 33, 104-108.	1.1	8

#	ARTICLE	IF	CITATIONS
181	The <scp>APEX</scp> trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12311.	1.1	8
182	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	1.8	8
183	A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-100.	0.4	8
184	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	2.9	8
185	The future of pharmacogenetics in the treatment of heart failure. <i>Pharmacogenomics</i> , 2015, 16, 1817-1827.	0.6	7
186	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
187	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	2.9	7
188	Myocardial ischaemia is associated with an elevated brain natriuretic peptide level even in the presence of left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 56-67.	2.9	6
189	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
190	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1009-1019.	2.9	6
191	Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. <i>Cardiovascular Therapeutics</i> , 2008, 26, 85-88.	1.1	5
192	Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. <i>Heart Rhythm</i> , 2012, 9, 505-510.	0.3	5
193	Underutilization of <scp>IV</scp> Nitrates in the Treatment of Acute Heart Failure. <i>Cardiovascular Therapeutics</i> , 2015, 33, 247-252.	1.1	5
194	Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011763.	1.3	5
195	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. <i>BMC Medicine</i> , 2021, 19, 21.	2.3	5
196	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	1.2	5
197	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
198	Surrogate markers of gut dysfunction are related to heart failure severity and outcome- from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	1.2	5

#	ARTICLE	IF	CITATIONS
199	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1171-1175.	2.3	4
200	Nicorandil-induced colovesical fistula in a patient with diverticular disease. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1737-1741.	0.2	4
201	Contrast Induced Nephropathy: Efficacy of matched hydration and forced diuresis for prevention in patients with impaired renal function undergoing coronary proceduresâ€“CINEMA trial. <i>IJC Heart and Vasculature</i> , 2022, 39, 100959.	0.6	4
202	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
203	Biomarker changes as surrogate endpoints in earlyâ€“phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
204	Global Array-Based Transcriptomics from Minimal Input RNA Utilising an Optimal RNA Isolation Process Combined with SPIA cDNA Probes. <i>PLoS ONE</i> , 2011, 6, e17625.	1.1	3
205	Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. <i>Current Heart Failure Reports</i> , 2014, 11, 31-39.	1.3	3
206	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.4	3
207	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3
208	Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs. <i>Diseases (Basel)</i> , 2021, 9, 10. <small>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</small>	1.0	3
209	Mitogen and Stress-Activated Kinases 1 and 2 Mediate Endothelial Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8655.	1.8	3
210	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK. <i>PLoS Medicine</i> , 2020, 17, e1003372.	3.9	3
211	Cardiotoxicity and Chemotherapyâ€“The Role of Precision Medicine. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 90.	1.0	3
212	Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 140-148.	1.0	2
213	Determinants of Exercise Capacity and Myocardial Perfusion Reserve in Asymptomatic Patients With Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 178-180.	2.3	2
214	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	0.7	2
215	Cardiac rehabilitation in heart failure with reduced ejection fraction: A â€“should take it and not leave itâ€“intervention. <i>American Heart Journal</i> , 2017, 192, e1-e2.	1.2	1
216	Effect of metformin on epicardial adipose tissue in patients with coronary artery disease without diabetes: A cardiac MRI substudy of the MET-remodel trial. <i>Obesity Medicine</i> , 2021, 24, 100349.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021, 144, e38-e39.	1.6	1
218	Guideline Adherence of $\beta$ -blocker Initiating Dose and its Consequence in Hospitalized Patients With Heart Failure With Reduced Ejection Fraction. <i>Frontiers in Pharmacology</i> , 2021, 12, 770239.	1.6	1
219	Heart failure with normal LVEF in BIOSTAT-CHF. <i>International Journal of Cardiology</i> , 2022, 364, 85-90.	0.8	1
220	Changing Times at Cardiovascular Therapeutics. <i>Cardiovascular Drug Reviews</i> , 2008, 26, 1-1.	4.4	0
221	The Role of the Heart Failure Specialist. , 2009, , 175-195.		0
222	65...Incidence and Monitoring of Adverse Drug Reactions in Long-Term Amiodarone Therapy: a Retrospective Analysis in Tayside, Scotland. <i>Heart</i> , 2015, 101, A35.2-A36.	1.2	0
223	Obituary. <i>Cardiovascular Therapeutics</i> , 2016, 34, 3-3.	1.1	0
224	What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply. <i>European Journal of Heart Failure</i> , 2019, 21, 132-133.	2.9	0
225	Reply. <i>Journal of Hypertension</i> , 2020, 38, 177-178.	0.3	0
226	Use of Population-Based Health Informatics Research to Improve Care for Patients with Cardiovascular Diseases. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 47.	1.0	0
227	Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial". <i>Circulation</i> , 2020, 141, e55-e56.	1.6	0
228	Medical Management of Rheumatic Heart Disease. , 2021, , 107-132.		0
229	Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: A prospective, randomised, open-label, blinded endpoint, crossover study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00258.	1.0	0
230	Management of Non-cardiac Co-morbidities in Chronic Heart Failure. , 2015, , 231-248.		0
231	Title is missing!. , 2020, 17, e1003372.		0
232	Title is missing!. , 2020, 17, e1003372.		0
233	Title is missing!. , 2020, 17, e1003372.		0
234	Title is missing!. , 2020, 17, e1003372.		0

#	ARTICLE	IF	CITATIONS
235	Title is missing!. , 2020, 17, e1003372.		0